These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7956947)

  • 121. Inflammatory Cytokine Signaling during Development of Pancreatic and Prostate Cancers.
    Liou GY
    J Immunol Res; 2017; 2017():7979637. PubMed ID: 29379802
    [TBL] [Abstract][Full Text] [Related]  

  • 122. A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands.
    Qin T; Barron L; Xia L; Huang H; Villarreal MM; Zwaagstra J; Collins C; Yang J; Zwieb C; Kodali R; Hinck CS; Kim SK; Reddick RL; Shu C; O'Connor-McCourt MD; Hinck AP; Sun LZ
    Oncotarget; 2016 Dec; 7(52):86087-86102. PubMed ID: 27863384
    [TBL] [Abstract][Full Text] [Related]  

  • 123. TGFβ Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis.
    Papageorgis P
    J Oncol; 2015; 2015():587193. PubMed ID: 25883652
    [TBL] [Abstract][Full Text] [Related]  

  • 124. AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction.
    Perez SA; Anastasopoulou EA; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2014 Nov; 63(11):1141-50. PubMed ID: 25052849
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.
    Karantanos T; Corn PG; Thompson TC
    Oncogene; 2013 Dec; 32(49):5501-11. PubMed ID: 23752182
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Inhibitor of differentiation 1 (Id1) and Id3 proteins play different roles in TGFβ effects on cell proliferation and migration in prostate cancer cells.
    Strong N; Millena AC; Walker L; Chaudhary J; Khan SA
    Prostate; 2013 May; 73(6):624-33. PubMed ID: 23060149
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells.
    Tang S; Moore ML; Grayson JM; Dubey P
    Cancer Res; 2012 Apr; 72(8):1975-85. PubMed ID: 22374980
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer.
    Richardsen E; Uglehus RD; Johnsen SH; Busund LT
    BMC Res Notes; 2012 Feb; 5():110. PubMed ID: 22353218
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Spotlight on differentially expressed genes in urinary bladder cancer.
    Zaravinos A; Lambrou GI; Volanis D; Delakas D; Spandidos DA
    PLoS One; 2011 Apr; 6(4):e18255. PubMed ID: 21483670
    [TBL] [Abstract][Full Text] [Related]  

  • 130. The immunoregulatory mechanisms of carcinoma for its survival and development.
    Du C; Wang Y
    J Exp Clin Cancer Res; 2011 Jan; 30(1):12. PubMed ID: 21255410
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Low levels of transforming growth factor-beta (TGF-beta) and reduced suppression of Th2-mediated inflammation in hyperreactive human onchocerciasis.
    Korten S; Hoerauf A; Kaifi JT; Büttner DW
    Parasitology; 2011 Jan; 138(1):35-45. PubMed ID: 20619070
    [TBL] [Abstract][Full Text] [Related]  

  • 132. More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer.
    Ajiboye S; Sissung TM; Sharifi N; Figg WD
    BJU Int; 2010 Apr; 105(7):913-6. PubMed ID: 20067462
    [TBL] [Abstract][Full Text] [Related]  

  • 133. TGF-beta insensitive dendritic cells: an efficient vaccine for murine prostate cancer.
    Wang FL; Qin WJ; Wen WH; Tian F; Song B; Zhang Q; Lee C; Zhong WD; Guo YL; Wang H
    Cancer Immunol Immunother; 2007 Nov; 56(11):1785-93. PubMed ID: 17473921
    [TBL] [Abstract][Full Text] [Related]  

  • 134. Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro.
    Brown KA; Aakre ME; Gorska AE; Price JO; Eltom SE; Pietenpol JA; Moses HL
    Breast Cancer Res; 2004; 6(3):R215-31. PubMed ID: 15084245
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Reversal of tumor-induced immunosuppression by TGF-beta inhibitors.
    Wojtowicz-Praga S
    Invest New Drugs; 2003 Feb; 21(1):21-32. PubMed ID: 12795527
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development.
    Charles LG; Xie YC; Restifo NP; Roessler B; Sanda MG
    World J Urol; 2000 Apr; 18(2):136-42. PubMed ID: 10854149
    [TBL] [Abstract][Full Text] [Related]  

  • 137. Interleukin-10: a cytokine used by tumors to escape immunosurveillance.
    Salazar-Onfray F
    Med Oncol; 1999 Jul; 16(2):86-94. PubMed ID: 10456656
    [TBL] [Abstract][Full Text] [Related]  

  • 138. Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma.
    Sehgal G; Hua J; Bernhard EJ; Sehgal I; Thompson TC; Muschel RJ
    Am J Pathol; 1998 Feb; 152(2):591-6. PubMed ID: 9466586
    [TBL] [Abstract][Full Text] [Related]  

  • 139. Expression of transforming growth factors beta-1, beta 2 and beta 3 in human bladder carcinomas.
    Eder IE; Stenzl A; Hobisch A; Cronauer MV; Bartsch G; Klocker H
    Br J Cancer; 1997; 75(12):1753-60. PubMed ID: 9192977
    [TBL] [Abstract][Full Text] [Related]  

  • 140. Expression of transforming growth factor-beta receptor type I and type II in rat ventral prostate and Dunning R3327 PAP adenocarcinoma in response to castration and oestrogen treatment.
    Wikström P; Bergh A; Damber JE
    Urol Res; 1997; 25(2):103-11. PubMed ID: 9144876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.